Groundbreaking new weight-loss drugs are transforming how Americans shed pounds, with nearly 18 million expected to take GLP-1 versions by 2029. This shift is partly due to the emergence of these medications, which may already be reversing America’s obesity crisis. According to a survey, the percentage of obese adults in the US has decreased from 41.9% in 2017-2020 to 40.3% in 2021-2023.
The pharmaceutical industry is adapting to this change, with some companies struggling to keep up. WeightWatchers’ CEO recently resigned after apologizing for past shaming of overweight individuals. Bariatric surgery has declined in popularity, prompting health systems to reassess their investments. The demand for joint replacements may also decrease as lighter bodies put less pressure on joints.
However, price and access remain significant challenges. List prices range from $936 to $1,349 per month, with insurance often not covering the full cost. Widespread shortages have prevented some patients from getting prescriptions filled, although the FDA has reported improvements.
The US government is considering authorizing Medicare to cover weight-loss drugs starting in 2026. If approved, this could greatly expand access to these medications. However, opponents argue that the extra costs are unsustainable. Experts also warn about the development of pill versions of GLP-1 drugs and the potential for supplement companies to capitalize on this trend.
Source: https://www.axios.com/2025/01/01/ozempic-weight-loss-medication-glp-1-wegovy-zepbound